The mode of action of 2-(thiazol-2-ylthio)-1β-methylcarbapenems against Pseudomonas aeruginosa: The impact of outer membrane permeability and the contribution of MexAB-OprM efflux system

Journal of Antibiotics

Volumn 60, Issue 2, 2007, Pages 129-135

  Eguchi, Ken ^a   Ueda, Yutaka ^a   Kanazawa, Katsunori ^a   Sunagawa, Makoto ^a   Gotoh, Naomasa ^b  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

2 (Thiazol 2 ylthio) 1 methylcarbapenem; MexAB OprM efflux system; OprD; Outer membrane permeability; Penicillin binding protein; Pseudomonas aeruginosa

Indexed keywords

2 (4 DIHYDROPYRROLYLTHIAZOL 2 YLTHIO) 1BETA METHYLCARBAPENEM DERIVATIVE; 2 (4 TETRAHYDROPYRIDINYLTHIAZOL 2 YLTHIO) 1BETA METHYLCARBAPENEM DERIVATIVE; BIAPENEM; CARBAPENEM DERIVATIVE; CHLORAMPHENICOL; EDETIC ACID; IMIPENEM; MEROPENEM; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN D2; OUTER MEMBRANE PROTEIN M; PANIPENEM; PENICILLIN BINDING PROTEIN; PROTEIN MEXAB; SMP 601; TETRACYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CARRIER PROTEIN; OPRM PROTEIN, PSEUDOMONAS AERUGINOSA; THIAZOLE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG TRANSPORT; IC 50; MEMBRANE CHANNEL; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; STRUCTURE ACTIVITY RELATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MEMBRANE; METABOLISM; MICROBIOLOGICAL EXAMINATION; PERMEABILITY;

PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; CARBAPENEMS; CHEMISTRY, PHYSICAL; MEMBRANE TRANSPORT PROTEINS; MEMBRANES; MICROBIAL SENSITIVITY TESTS; PENICILLIN-BINDING PROTEINS; PERMEABILITY; PSEUDOMONAS AERUGINOSA; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 34249720498     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2007.12     Document Type: Article

References (18)

1. Arakawa Y, Ike Y, Nagasawa M, Shibata N, Doi Y, Shibayama K, Yagi T, Kurata T Trends in antimicrobial-drug resistance in Japan. Emerg Infect Dis 6: 572-575 (2000)
2. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 119: 397S-404S (2001)
3. Ueda Y, Kanazawa K, Eguchi K, Takemoto K, Eriguchi Y, Sunagawa M. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob Agents Chemother 49: 4185-4196 (2005)
4. Ueda Y, Itoh M, Sasaki A, Sunagawa M. SM-216601, a novel parenteral 1β-methylcarbapenem: structure-activity relationships of antibacterial activity and neurotoxicity in mice. J Antibiot 58: 118-140 (2005)
5. Sumita Y, Yamaga H, Sunagawa M. The effect of 1β-methyl substituent and the basicity in C-2 side chain in carbapenem antibiotics on the activity against Pseudomonas aeruginosa oprD2 and nalB mutants. J Antibiot 48: 89-91 (1995)
6. Zhao G, Meier TI, Kahl SD, Gee KR, Blaszczak LC. BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins. Antimicrob Agents Chemother 43: 1124-1128 (1999)
7. Morikawa Y, Kitazato M, Mitsuyama J, Mizunaga S, Minami S, Watanabe Y. In vitro activities of piperacillin against β-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother 48: 1229-1234 (2004)
8. Sumita Y, Fukasawa M, Okuda T Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes. J Antibiot 43: 314-320 (1990)
9. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-fifth edition. National Committee for Clinical Laboratory Standards 20: M7-A5 (2000)
10. Kahan FM, Kropp H, Sundelof JG, Birnbaum J. Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother 12 (Suppl D): 1-35 (1983)
11. Gotoh N, Nishino T Decreases of the susceptibility to low molecular weight β-lactam antibiotics in imipenem-resistant Pseudomonas aeruginosa mutants: role of outer membrane protein D2 in their diffusion. J Antimicrob Chemother 25: 191-198 (1990)
12. Nagao Y, Nagase Y, Kumagai T, Matsunaga H, Abe T, Shimada O, Hayashi T, Inoue Y. β-Lactams. 3. Asymmetric total synthesis of new non-natural 1β-methylcarbapenems exhibiting strong antimicrobial activities and stability against human renal dehydropeptidase-I. J Org Chem 57: 4243-4249 (1992)
13. Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 34: 52-57 (1990)
14. Li XZ, Ma D, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrob Agents Chemother 38: 1742-1752 (1994)
15. Li XZ, Nikaido H, Poole K. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother 39: 1948-1953 (1995)
16. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 47: 247-250 (2001)
17. Li XZ, Zhang L, Poole K. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother 45: 433-436 (2000)
18. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev 56: 395-411 (1992)